Evaluating von Willebrand factor and ADAMTS13 levels in thalassemia major patients and assessing a possible association with Thrombospondin-1.
ADAMTS13
Thrombospondin-1
Von Willebrand factor
thalassemia
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
27
01
2023
accepted:
27
06
2023
medline:
17
11
2023
pubmed:
13
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
Alterations in the endothelium and endothelial adhesion proteins such as von Willebrand factor (vWF) play major roles in hypercoagulability in thalassemia. vWF protein release leads to platelet aggregation and thrombi formation at the site of vascular injury. It is then degraded by the proteolytic enzyme ADAMTS13. Thrombospondin-1 is a multifactorial glycoprotein, which was reported to compete with ADAMTS13 for sites of vWF proteolysis. In this study, levels of vWF, ADAMTS13, and TSP-1 proteins were determined in β-thalassemia major patients. A possible association between TSP-1 and vWF and ADAMTS-13 was also evaluated. The study was conducted on 80 β-thalassemia major patients and 80 age and sex matched healthy controls. The 80 patients were sub-divided into two groups; splenectomised and non-splenectomised. vWF, ADAMTS13 and TSP-1 plasma level were measured using ELISA technique. There was no significant difference in vWF and TSP-1 levels between patients and controls (p > 0.05). However, ADAMTS13 levels and ADAMTS13 activity/vWF antigen ratio were significantly higher in patients compared to controls (p < 0.05). VWF antigen and TSP-1 level were significantly higher in splenectomised patients (p = 0.025 and p < 0.001, respectively). We also observed a significant decrease in ADAMTS13 activity/vWF antigen ratio among splenectomised compared to non- splenectomised patients (p = 0.019). Correlation analysis showed a significant negative correlation between TSP-1 and vWF Collagen Binding Activity (r = -0.394, p = 0.021) and a positive correlation with ADAMTS13 activity/vWF antigen ratio (r = 0.356, p = 0.039) in splenectomised compared to non- splenectomised patients. Our findings highlight the adequacy of patient management protocols for β-TM in Kuwait as patients presented with comparable levels of platelets, vWF and TSP-1 compared to normal controls. The reported increase in ADAMTS13 in patients may be required to maintain normal levels of vWF. Although no active thrombotic episodes were reported at the time of the study, the significant rise in platelets, vWF:Ag and TSP-1 levels in splenectomised patients may indicate a tendency towards hypercoagulability. Monitoring of splenectomised patients is recommended.
Substances chimiques
ADAMTS13 Protein
EC 3.4.24.87
ADAMTS13 protein, human
EC 3.4.24.87
Thrombospondin 1
0
von Willebrand Factor
0
SPZ1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
945-952Subventions
Organisme : College of Graduate Studies, Kuwait University
ID : YN02/21
Organisme : Kuwait University, Research Sector
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Sharma DC, Arya A. Overview on thalassemia: a review article. Med Res Chron. 2017;4(3):325-337.
Bayanzay K, Alzoebie L. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. J Blood Med. 2016;7:159-169. doi:10.2147/jbm.s61540
Modell B. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;2008(6):480-487. doi:10.2471/blt.06.036673
Vasilopoulou M, Stafylidis C, Politou M. The thrombotic spectrum of B-thalassemia. Thromb Update. 2022;7:100102. doi:10.1016/j.tru.2022.100102
Natesirinilkul R. Thromboembolism in beta-thalassemia disease. Beta Thalassemia. InTechOpen; 2020. doi:10.5772/intechopen.89313
Abbassy H, Ghallab O. Candidate markers for thromboembolic complications in adult Egyptian patients with β-thalassemia. Egypt J Haematol. 2017;42(2):64. doi:10.4103/ejh.ejh_12_17
Butthep P, Bunyaratvej A, Funahara Y, et al. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health. 1997;28(Suppl 3):141-148.
Fayed MA, Abdel-Hady HE-S, Hafez MM, Salama OS, Al-Tonbary YA. Study of platelet activation, hypercoagulable state, and the association with pulmonary hypertension in children with β-thalassemia. Hematol Oncol Stem Cell Ther. 2018;11(2):65-74. doi:10.1016/j.hemonc.2017.05.028
Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019-2028. doi:10.1182/blood-2014-06-528406
Ward S, O'Sullivan JM, O'Donnell JS. Von Willebrand factor sialylation-a critical regulator of biological function. J Thromb Haemost. 2019;17(7):1018-1029. doi:10.1111/jth.14471
Abd El-samee H, Bassiouny N, Nabih NA. Impact of activated monocyte and endothelial dysfunction on coagulopathy in Egyptian adult beta thalassemic patients. Hematol Rep. 2020;12(2):8365. doi:10.4081/hr.2020.8365
Hamed AA, Darwish YW, El-Sayed MH. ADAMTS13 levels in young patients with β-thalassemia major. Clin Appl Thromb Hemost. 2014;21(6):527-532. doi:10.1177/1076029614558112
Kelwick R, Desanlis I, Wheeler GN, Edwards DR. The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. Genome Biol. 2015;16(1):113. doi:10.1186/s13059-015-0676-3
Wang A, Liu F, Dong N, et al. Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro. Thromb Res. 2010;126(4):e260-e265. doi:10.1016/j.thromres.2010.07.009
Krishna SM, Golledge J. The role of thrombospondin-1 in cardiovascular health and pathology. Int J Cardiol. 2013;168(2):692-706. doi:10.1016/j.ijcard.2013.04.139
Prakash P, Kulkarni PP, Chauhan AK. Thrombospondin 1 requires von Willebrand factor to modulate arterial thrombosis in mice. Blood. 2015;125(2):399-406. doi:10.1182/blood-2014-06-581942
Novelli EM, Kato GJ, Hildesheim ME, et al. Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica. 2013;98(11):e132-e134. doi:10.3324/haematol.2013.092635
Al-Harbi KM, Shalaby SA, Baghdadi HH. Monocytes activation and some Haemostatic parameters in cases of β-thalassemia. J Basic Appl Sci Res. 2011;1:727-733.
Adly AA, El-Sherif NH, Ismail EA, et al. Vascular dysfunction in patients with young β-thalassemia. Clin Appl Thromb Hemost. 2014;21(8):733-744. doi:10.1177/1076029614541515
Rusu L, Minshall RD. Endothelial cell von Willebrand factor secretion in health and cardiovascular disease. Endothelial Dysfunction-Old Concepts and New Challenges. InTechOpen; 2018. doi:10.5772/intechopen.74029
Bonnefoy A, Moura R, Hoylaerts MF. Thrombospondins: from structure to therapeutics. Cell Mol Life Sci. 2008;65(5):713-727. doi:10.1007/s00018-007-7487-y
Bonnefoy A, Daenens K, Feys HB, et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood. 2006;107(3):955-964. doi:10.1182/blood-2004-12-4856
Al-Awadhi A, Adekile A, Marouf R. Relationship of thrombospondin 1 to von Willebrand factor and ADAMTS-13 in sickle cell disease patients of Arab ethnicity. Acta Haematol. 2020;144(2):182-189. doi:10.1159/000508521
Bonnet S, Guédon A, Ribeil J-A, Suarez F, Tamburini J, Gaujoux S. Indications and outcome of splenectomy in hematologic disease. J Visc Surg. 2017;154(6):421-429. doi:10.1016/j.jviscsurg.2017.06.011
Cappellini M-D, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Thalassaemia International Federation; 2014.
Chapman J, Goyal A, Azevedo AM. Splenomegaly. StatPearls. StatPearls Publishing; 2022.
Kapila V, Wehrle CJ, Tuma F. Physiology, spleen. StatPearls. StatPearls Publishing; 2022.
Saleh HA, Alkhateep YM, Mohammed AN. Role of splenectomy in thalassemic patients. Menoufia Med J. 2018;31(1):118-125.
Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, Eleftheriou A. Thalassaemia international federation guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere. 2022;6(8):e732. doi:10.1097/HS9.0000000000000732
Tahir F, Ahmed J, Malik F. Post-splenectomy sepsis: a review of the literature. Cureus. 2020;12:e6898. doi:10.7759/cureus.6898
Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010;8(10):2152-2158. doi:10.1111/j.1538-7836.2010.03940.x
Ageeli M, Khawaji M, Hazzazi A, et al. Clinical and hematological features among β-thalassemia major patients in Jazan region: a hospital-based study. J Family Med Primary Care. 2020;9(1):412-417. doi:10.4103/jfmpc.jfmpc_1007_19
Weng J, Brown CV, Rhee P, et al. White blood cell and platelet counts can be used to differentiate between infection and the normal response after splenectomy for trauma: prospective validation. J Trauma: Injury Infection Crit Care. 2005;59(5):1076-1080. doi:10.1097/01.ta.0000189001.00670.d2
Buzelé R, Barbier L, Sauvanet A, Fantin B. Medical complications following splenectomy. J Visc Surg. 2016;153(4):277-286. doi:10.1016/j.jviscsurg.2016.04.013
Yang Z, Guo T, Zhu D-L, Zheng S, Han D-D, Chen Y. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis. Hepatoma Res. 2020;6:37-49. doi:10.20517/2394-5079.2020.09
Kimmig LM, Palevsky HI. Review of the association between splenectomy and chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc. 2016;13(6):945-954. doi:10.1513/annalsats.201512-826fr
Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood. 2018;132(17):1781-1791. doi:10.1182/blood-2018-06-818187